AzurRx BioPharma

AzurRx to acquire First Wave Bio for $229m
Pharmaceutical Business Review
Tue, 09/14/21 - 10:50 am
M&A
AzurRx BioPharma
First Wave Bio
AzurRx BioPharma Is An Ultra-High-Risk IPO
Seeking Alpha
Fri, 08/19/16 - 11:42 am
AzurRx BioPharma
IPOs
exocrine pancreatic insufficiency